Federated Investors Inc. PA trimmed its position in Zogenix, Inc. (NASDAQ:ZGNX) by 16.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 984,561 shares of the company’s stock after selling 195,513 shares during the quarter. Federated Investors Inc. PA’s holdings in Zogenix were worth $48,834,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Scopia Capital Management LP boosted its holdings in shares of Zogenix by 51.3% in the third quarter. Scopia Capital Management LP now owns 5,306,514 shares of the company’s stock worth $263,203,000 after buying an additional 1,798,786 shares during the period. BlackRock Inc. boosted its holdings in shares of Zogenix by 22.6% in the third quarter. BlackRock Inc. now owns 3,604,224 shares of the company’s stock worth $178,771,000 after buying an additional 664,681 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Zogenix by 65.9% in the third quarter. Bank of New York Mellon Corp now owns 2,546,543 shares of the company’s stock worth $126,308,000 after buying an additional 1,011,898 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Zogenix by 18.1% in the third quarter. Vanguard Group Inc. now owns 2,070,386 shares of the company’s stock worth $102,691,000 after buying an additional 318,010 shares during the period. Finally, FMR LLC boosted its holdings in shares of Zogenix by 0.7% in the third quarter. FMR LLC now owns 1,286,739 shares of the company’s stock worth $63,823,000 after buying an additional 8,454 shares during the period.

ZGNX stock opened at $41.44 on Friday. The company has a market cap of $1.76 billion, a P/E ratio of -10.31 and a beta of 1.84. Zogenix, Inc. has a 52 week low of $33.42 and a 52 week high of $62.75.

Zogenix (NASDAQ:ZGNX) last posted its earnings results on Thursday, November 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.20). During the same quarter in the previous year, the business posted ($1.68) EPS. Analysts anticipate that Zogenix, Inc. will post -3.84 EPS for the current year.

Several research firms recently commented on ZGNX. LADENBURG THALM/SH SH began coverage on shares of Zogenix in a report on Thursday, August 23rd. They set a “buy” rating and a $71.00 price target for the company. Bank of America began coverage on shares of Zogenix in a report on Friday, September 14th. They set a “buy” rating and a $63.00 price target for the company. Leerink Swann set a $93.00 price target on shares of Zogenix and gave the stock a “buy” rating in a report on Saturday, October 6th. B. Riley began coverage on shares of Zogenix in a report on Friday, September 7th. They set a “buy” rating and a $116.00 price target for the company. Finally, Mizuho restated a “buy” rating and set a $69.00 price target on shares of Zogenix in a report on Friday, August 24th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $70.00.

In other Zogenix news, EVP Gail M. Farfel sold 6,961 shares of Zogenix stock in a transaction that occurred on Thursday, October 4th. The shares were sold at an average price of $43.23, for a total value of $300,924.03. Following the completion of the sale, the executive vice president now directly owns 14,104 shares in the company, valued at $609,715.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Erle T. Mast sold 1,468 shares of Zogenix stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $42.08, for a total transaction of $61,773.44. Following the completion of the sale, the director now owns 3,027 shares of the company’s stock, valued at $127,376.16. The disclosure for this sale can be found here. 4.60% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/12/16/zogenix-inc-zgnx-holdings-lowered-by-federated-investors-inc-pa.html.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Read More: Roth IRA

Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.